402-13-1

Usage

Chemical Properties

Light yellow solid

InChI:InChI=1/C8H6F3NO2/c9-8(10,11)4-1-2-5(7(13)14)6(12)3-4/h1-3H,12H2,(H,13,14)/p-1

Upstream product

• 320-94-5 2-nitro-4-trifluoromethylbenzoic acid 
• 404-83-1 N-(3-trifluoromethylphenyl)-2-oxyiminoacetamide 
• 343-69-1 6-(Trifluoromethyl)-1H-indol-2,3-dione 
• 713-41-7 2-amino-4-(trifluoromethyl)benzamide 
• 455-24-3 4-trifluoromethylbenzoic acid 
• 778-94-9 2-nitro-4-trifluoromethyl-benzonitrile 
• 61500-87-6 methyl 2-Amino-4-(trifluoromethyl)benzoate 
• 65754-26-9 2-methyl-5-trifluoromethylnitrobenzene 
• 400-98-6 4-trifluoromethyl-2-nitroaniline 
• 98-16-8 3-trifluoromethylaniline 
• 318-45-6 3-methyl-7-trifluoromethyl-quinolin-4-ol 

Downstream Products

• 6219-97-2 N-(5,8,14-trioxo-11-trifluoromethyl-5,8,13,14-tetrahydro-naphth[2,3-c]acridin-6-yl)-benzamide 
• 455-24-3 4-trifluoromethylbenzoic acid 
• 396-02-1 2,4-dichloro-7-(trifluoromethyl)quinazoline 
• 3833-78-1 7-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione 
• 61500-87-6 methyl 2-Amino-4-(trifluoromethyl)benzoate 
• 85167-58-4 C₁₆H₈F₆N₄O₂ 
• 16499-58-4 4-hydroxy-7-trifluoromethylquinazoline 
• 188054-34-4 4-(trifluoromethyl)-2-{[2-(methoxycarbonyl)phenyl]amino}benzoic acid 
• 85167-59-5 C₁₈H₁₃F₆N₃O₄ 
• 328-89-2 2-bromo-4-trifluoromethyl-benzoic acid 
• 186602-93-7 [2-amino-4-(trifluoromethyl)phenyl]methan-1-ol 
• 97928-01-3 7-trifluoromethyl-1,2-dihydro-3,1-benzoxazine-2,4-dione 
• 65568-55-0 2-amino-α,α,α-trifluoro-p-toluic acid ethyl ester 
• 916168-23-5 C₁₃H₁₄F₃NO₃ 

Relevant academic research and scientific papers

Discovery of Novel Tacrine-Pyrimidone Hybrids as Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer's Disease

Based on a multitarget strategy, a series of novel tacrine-pyrimidone hybrids were identified for the potential treatment of Alzheimer's disease (AD). Biological evaluation results demonstrated that these hybrids exhibited significant inhibitory activities toward acetylcholinesterase (AChE) and glycogen synthase kinase 3 (GSK-3). The optimal compound 27g possessed excellent dual AChE/GSK-3 inhibition both in terms of potency and equilibrium (AChE: IC50 = 51.1 nM; GSK-3β: IC50 = 89.3 nM) and displayed significant amelioration on cognitive deficits in scopolamine-induced amnesia mice and efficient reduction against phosphorylation of tau protein on Ser-199 and Ser-396 sites in glyceraldehyde (GA)-stimulated differentiated SH-SY5Y cells. Furthermore, compound 27g exhibited eligible pharmacokinetic properties, good kinase selectivity, and moderate neuroprotection against GA-induced reduction in cell viability and neurite damage in SH-SY5Y-derived neurons. The multifunctional profiles of compound 27g suggest that it deserves further investigation as a promising lead for the prospective treatment of AD.

Selenium-catalyzed intramolecular atom- And redox-economical transformation ofo-nitrotoluenes into anthranilic acids

Anthranilic acids (AAs) are significant basic chemicals used in pharmaceuticals, agrochemicals, dyes, fragrances,etc. Superfluous steps are always involved in obtaining AAs. Herein, we demonstrate a straightforward strategy to transform abundanto-nitrotoluenes into biologically and pharmaceutically significant AAs without any extra reductants, oxidants and protecting groups. Various sensitive groups, such as halogens, sulfide, aldehyde, pyridines, quinolines,etc., can be tolerated in this transformation. A hundred-gram-scale operation is realized efficiently with almost quantitative selenium recycling. Further mechanistic studies and DFT calculations disclosed the proposed atom-exchange processes and the key roles of the selenium species.

Chemo-selective reduction of nitro and nitrile compounds using Ni nanoparticles immobilized on hyperbranched polymer-functionalized magnetic nanoparticles

The nitro and nitrile groups in aromatic and aliphatic compounds containing various reducible substituents such as carboxylic acid, ketone, aldehyde and halogen are selectively reduced to the corresponding amines in water as a green solvent with excellent yields by employing NaBH4 in the presence of Fe3O4@PAMAM/Ni(0)-b-PEG nanocatalyst. The morphology and structural features of the catalyst were characterized using various microscopic and spectroscopic techniques. The designed catalyst system because of it being covered with hydrophilic polymers is soluble in a wide range of solvents (e.g. water and ethanol) and suitable for immobilizing and stabilizing Ni nanoparticles in aqueous mediums. In addition, the catalyst can be easily recovered from a reaction mixture by applying an external magnetic field and can be reused up to six runs without significant loss of activity.

Design and development of bioinspired guanine-based organic catalyst for asymmetric catalysis

Design, preparation, and studies of a family of new organic catalysts are presented. The design of the catalysts is inspired by the ability of DNA nucleobases to develop precise and explicit hydrogen bonds. We have shown that this phenomenon can be used to create a useful organic catalyst that demonstrates a recognition pattern similar to those of common organic substrates. A selected bifunctional catalyst based on a guanine structure has been shown to catalyze the conjugate addition of 1,3-dicarbonyl compounds to various nitroalkenes, providing the products in good yields and enantioselectivities.

5, 7-DIHYDRO- 6H-PYRIMIDO [ 5, 4-D] [ 1 ] BENZAZEPIN-6-THIONES AS PLK INHIBITORS

This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, and R6 are as described in the specification. The compounds are inhibitors of PLK and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

This present disclosure relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present disclosure also provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

INHIBITORS OF PROTEIN KINASES

The present invention is directed to a compound having the formula (I) wherein R1, R2, R3, R4, G, and Q are defined herein. The compounds of the present invention are useful as inhibitors of protein kinases. The present invention is also directed to compositions comprising a compound according to the above formula. The present invention is also directed to compounds that stabilize the open conformation of a protein kinase, a crystallized protein kinase ih the open conformation, and uses thereof. The compounds and compositions described herein are useful for treating and preventing an inflammatory condition or disease.

1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS

The present invention relates to l H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as AMPA-receptor ligands, in particular for the treatment of epilepsy or schizophrenia, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) and combinations comprising compounds of formula (I) are disclosed.

QUINAZOLINONES

Disclosed are compounds of formula (I), wherein R, R1, R2, R3, R4, R5, R6, R7, R8, Z1, Z2, Z3, k, and Y1 have the meanings indicated in claim 1. Said compounds can be used for the treatment of tumors, among other things.

Process for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl) acetylguanidine derivatives

A method and apparatus for preventing board warpage during the application and curing or drying of liquid epoxies, or the like, on printed circuit boards using a clamping fixture assembly, which includes at least one clamping fixture support and at least one clamping fixture overlay. If desired, a plurality of printed circuit boards may be processed using an appropriate clamping fixture assembly. Furthermore, the clamping fixture may be constructed so a slight bow or curvature thereof can counter either a convex or concave bow or curvature of the printed circuit board. In the method, at least one printed circuit board is mounted to a clamping fixture support whereby a clamping fixture overlay is placed on top of the first printed circuit board.